ArticleFrontiers in oncology2026
Risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the risk factors for cardiotoxicity induced by trastuzumab in human epidermal growth factor receptor 2 (HER2) -positive breast cancer patients and provide a basis for early clinical intervention. Methods: A retrospective analysis was conducted on 298 HER2-positive breast cancer patients treated with trastuzumab. Clinical data including age, history of cardiovascular disease, combined chemotherapy regimens, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and baseline left ventricular ejection fraction (LVEF) were collected. Multivariate logistic regression was used to identify independent risk factors for cardiotoxicity. Results: A total of 65 patients (21.8%) developed cardiotoxicity. Multivariate analysis showed that age ≥60 years (OR = 1.97, 95%CI: 1.21-3.22), history of hypertension (OR = 2.10, 95%CI: 1.24-3.56), combined anthracycline therapy (OR = 3.06, 95%CI: 1.67-5.62), baseline NT-proBNP ≥200 pg/ml (OR = 2.34, 95%CI: 1.35-4.05), and baseline LVEF ≤55% (OR = 2.51, 95%CI: 1.42-4.43) were independent risk factors for trastuzumab-induced cardiotoxicity (all P < 0.05). Conclusion: These findings enable risk stratification before trastuzumab initiation. Future research should validate a predictive model incorporating these factors and assess cardioprotective strategies, thereby translating risk assessment into actionable protocols to optimize cardiac safety without compromising oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.